CERo announces SCRI as main site for trial of CER-1236 to treat AML
CERo Therapeutics has announced that Colorado Blood Cancer Institute’s (CBCI) Sarah Cannon Research Institute (SCRI), US, will be the main site …
-
-
Caribou cuts pipeline and workforce to focus on lead CAR-T programmes
Caribou Biosciences is narrowing its pipeline and reducing its workforce by approximately 32% amid continued challenges in the cell and …
-
Renibus completes enrolment in RBT-1 trial to reduce post-cardiac surgery risk
Renibus Therapeutics has completed subject enrolment for the randomised Phase III PROTECT trial, assessing RBT-1 (stannic protoporfin/iron sucrose) in minimising …
-
Clinical ink introduces AI-powered trial analytics dashboard
Clinical ink has launched the AI-powered, fully integrated analytics dashboard, TrialLens, designed to transform the visualisation, querying, and interpretation of …
-
ESCMID Global 2025: Initial ABI-5366 data supports monthly dosing for genital herpes
Early clinical and preclinical findings presented at the 35th European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global conference …
-
Sanofi axes development of oral TNF inhibitor as monotherapy following Phase II fail
Sanofi will halt the development of its oral tumour necrosis factor (TNF) inhibitor balinatunfib as a monotherapy after it failed …
-
Dosing begins in Tiziana Life Sciences’ trial of foralumab for na-SPMS
Tiziana Life Sciences has announced the commencement of dosing in the fourth clinical site of the company’s Phase II trial …
-
Redefining the future of clinical trials in oncology
Next month, experts from big and small pharmaceutical and biotech companies, contract research organisations (CROs), cancer counselling and resource centers …
-
Akeso and Summit notch another Phase III win with their Keytruda competitor
Akeso Pharmaceuticals and Summit Therapeutics have reported that their PD-1/VEGF bispecific antibody has met the primary endpoint in a Phase …
-
Cytovation secures $6m for trial of CY-101 to treat adrenocortical carcinoma
Norwegian company Cytovation has secured Nkr62m ($6m) to progress CY-101 into a multi-national Phase II trial, targeting individuals with adrenocortical …
-
7 key questions to consider for your next IND filing
When preparing for an upcoming drug development program, leveraging existing knowledge and strategies to streamline the process from concept to …
-
Lokavant launches Spectrum v15 trial forecasting solution
Lokavant has launched the AI-powered clinical trial forecasting solution, Spectrum v15, to dispel uncertainty in the feasibility of studies. The solution …
-
ESCMID Global 2025: Gepotidacin is non-inferior to leading gonorrhoea dual therapy
At the 35th European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global conference in Vienna, Austria, Dr Janet Wilson …
-
WHO publishes first-ever guidelines for meningitis diagnosis and care
Meningitis is a life-threatening condition caused by a bacterial or viral infection. Meningitis is an infection of the protective membranes …
-
Synthetic hormones and the future of contraception
The landscape of contraception for women has seen minimal change over the past 50 years, with successive generations often relying …
